ArticleACS applied materials & interfaces2025
Refillable Intraocular Drug-Eluting Implant.
Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The increasing incidence of ophthalmic diseases has led the need for multiple dosage regimens, which can cause patient discomfort and noncompliance due to the frequency of medication administration. Still, ophthalmic drug delivery methods, such as eye drops and intravitreal injection, pose challenges, such as poor bioavailability, short half-life, and patient compliance. In this study, we introduce a novel refillable intracapsular drug-eluting reservoir for the long-term management of ocular diseases. This device, made of medical-grade silicone and stainless steel, has features to contour the lens capsule to facilitate microincisional implantation. Rheological and mechanical analyses of the silicone revealed the optimized conditions for the device construction and its application compliance for ocular intracapsular implantation. Furthermore, in vitro release studies exhibit controlled drug release, the kinetics of which were along with Fickian diffusion, while ex vivo implantation testing shows that the device can be easily delivered and placed at the time of cataract surgery. Taken altogether, the developed implant holds significant potential for improving therapeutic outcomes while offering a practical surgical application and compliance of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.